MedTrace Logo

Colchicine and CRP in Atrial Fibrillation and AF Ablation

NCT01755949 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2019-05-09

Study results available
· View outcomes & findings →

Summary

Colchicine will lower C-reactive protein (CRP) in chronic atrial fibrillation and reduce the rise in CRP which occurs following atrial fibrillation ablation

Conditions

Interventions

DRUG

Colchicine, 0.6 mg PO BID

Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo

DRUG

Matching placebo

Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug

Sponsors & Collaborators

  • Takeda

    collaborator INDUSTRY

  • Detiger Funds

    collaborator UNKNOWN

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Joseph L. Blackshear, MD · Consultant in Cardiovascular Diseases

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2016-12-06
Completion
2016-12-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01755949 on ClinicalTrials.gov